We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
+15.25%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$126M
AUM Growth
+$10.2M
Cap. Flow
-$1.82M
Cap. Flow %
-1.44%
Top 10 Hldgs %
41.21%
Holding
109
New
16
Increased
15
Reduced
23
Closed
15

Top Buys

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$2.72M
2
SYRE icon
Spyre Therapeutics
SYRE
+$2.69M
3
CYNA
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
+$2.28M
4
TNDM icon
Tandem Diabetes Care
TNDM
+$2.22M
5
LOXO
Loxo Oncology, Inc
LOXO
+$1.57M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$2.45M
2
MRNS
Marinus Pharmaceuticals, Inc
MRNS
+$2.19M
3
BEAT
BioTelemetry, Inc.
BEAT
+$2M
4
MASI
Masimo
MASI
+$1.7M
5
CYAD
Celyad Oncology SA American Depositary Shares
CYAD
+$1.32M

Sector Composition

Rank Sector Weight
1 Healthcare 84.62%
2 Miscellaneous 15.38%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NXTM
1
DELISTED
NxStage Medical Inc.
NXTM
$7.73M 6.13%
356,509
-40,045
-10% -$714K
ATRC icon
2
AtriCure
ATRC
$2.47B
$7.26M 5.76%
513,946
+25,500
+5% +$389K
VTAE
3
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$7.12M 5.65%
660,188
-127,185
-16% -$1.09M
DERM
4
DELISTED
Dermira, Inc.
DERM
$5.66M 4.49%
193,642
+21,761
+13% +$600K
ABBV icon
5
AbbVie
ABBV
$451B
$4.73M 3.75%
76,331
-40,250
-35% -$2.45M
ALDR
6
DELISTED
Alder Biopharmaceuticals
ALDR
$4.13M 3.27%
165,313
+25,000
+18% +$676K
RIGL icon
7
Rigel Pharmaceuticals
RIGL
$868M
$4.12M 3.26%
184,709
-2,940
-2% -$73.1K
NVAX icon
8
Novavax
NVAX
$1.53B
$4M 3.17%
27,500
-175
-0.6% -$20.1K
CYNA
9
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$3.72M 2.95%
222,359
+169,418
+320% +$2.28M
LKFT
10
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$3.53M 2.79%
63,568
-2,000
-3% -$101K
NBIX icon
11
Neurocrine Biosciences
NBIX
$15.7B
$3.43M 2.72%
75,503
-797
-1% -$36.7K
AERI
12
DELISTED
Aerie Pharmaceuticals
AERI
$2.83M 2.24%
160,869
-18,900
-11% -$306K
PODD icon
13
Insulet
PODD
$10.1B
$2.79M 2.21%
92,164
-13,854
-13% -$431K
TSRO
14
DELISTED
TESARO, Inc.
TSRO
$2.52M 2%
+30,000
New +$1.34M
LOXO
15
DELISTED
Loxo Oncology, Inc
LOXO
$2.36M 1.87%
101,966
+62,966
+161% +$1.57M
AGTC
16
DELISTED
Applied Genetic Technologies Corporation
AGTC
$2.36M 1.87%
167,192
– –
TNDM icon
17
Tandem Diabetes Care
TNDM
$1.49B
$2.36M 1.87%
31,276
+27,621
+756% +$2.22M
IMMU
18
DELISTED
Immunomedics Inc
IMMU
$1.89M 1.5%
+815,000
New +$2.72M
ACHN
19
DELISTED
Achillion Pharmaceuticals
ACHN
$1.84M 1.46%
236,500
– –
SYRE icon
20
Spyre Therapeutics
SYRE
$7.97B
$1.7M 1.35%
+14,016
New +$2.69M
BEAT
21
DELISTED
BioTelemetry, Inc.
BEAT
$1.63M 1.29%
100,000
-135,645
-58% -$2M
ZGNX
22
DELISTED
Zogenix, Inc.
ZGNX
$1.59M 1.26%
197,538
+118,138
+149% +$1.15M
BSTC
23
DELISTED
BioSpecifics Technologies Corp.
BSTC
$1.59M 1.26%
39,704
– –
IBB icon
24
iShares Biotechnology ETF
IBB
$10.5B
$1.54M 1.22%
18,000
– –
SPNC
25
DELISTED
Spectranetics Corp
SPNC
$1.49M 1.18%
79,812
– –
1
2 3 4 5

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q2 2016 Portfolio in Review

As of Q2 2016, DAFNA Capital Management held 109 positions worth $126M, up 8.8% from $116M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

DAFNA Capital Management's Q2 2016 filing shows 16 new, 15 increased, 23 reduced and 15 closed positions. Its largest new stake was Immunomedics Inc: 815,000 shares worth $1.89M. The largest sale was AbbVie, an estimated $2.45M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 86% a quarter earlier, followed by Miscellaneous and Financials.

  • DAFNA Capital Management's largest Q2 2016 buy was Immunomedics Inc: 815,000 shares worth $1.89M.
  • DAFNA Capital Management added most to CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA) in Q2 2016, an estimated $2.28M increase.
  • DAFNA Capital Management's biggest Q2 2016 reduction was AbbVie, cutting an estimated $2.45M.
  • DAFNA Capital Management fully exited Celyad Oncology SA American Depositary Shares in Q2 2016, selling an estimated $1.32M.
  • DAFNA Capital Management's ten largest holdings make up 41% of its $126M portfolio in Q2 2016.
  • DAFNA Capital Management opened 16 new positions and closed 15 in Q2 2016.
  • DAFNA Capital Management's portfolio value rose 8.8% quarter-over-quarter to $126M.

Based on DAFNA Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.